Literature DB >> 10891465

Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia.

L Karawajew1, V Ruppert, C Wuchter, A Kösser, M Schrappe, B Dörken, W D Ludwig.   

Abstract

In normal T-cell development, IL-7 plays a nonredundant role as an antiapoptic factor by regulating Bcl-2 expression in pro-T cells. In the current study, we addressed the roles of IL-7 and related cytokines as apoptosis-modulating factors in precursor T-cell acute lymphoblastic leukemia (T-ALL). To this end, leukemic blasts from pediatric patients with T-ALL were prospectively investigated as to their responsiveness to IL-7, IL-4, and IL-2 (in terms of modulation of spontaneous apoptosis, assessed by flow cytometry), cytokine receptor expression profiles, and expression levels of Bcl-2 and Bax proteins. IL-7, in contrast to IL-4 and IL-2, was highly efficient in apoptosis inhibition, and this effect correlated with the expression levels of IL-7Ralpha chain and with the up-regulation of Bcl-2 protein expression (P <.0001). Subclassification of T-ALL samples (n = 130) according to their in vitro IL-7 responses revealed that IL-7 refractory samples were more frequently positive for CD34 (P <.0001) and the myeloid-associated antigen CD33 (P =.01), whereas IL-7 responsiveness was associated with an expression of more mature differentiation-associated T-cell antigens (CD1a, surface CD3, CD4/8; P <.05). Furthermore, the extent of apoptosis inhibition by IL-7 in vitro quantitatively correlated with early cytoreduction as determined by the prednisone peripheral blood response on day 8 and cytoreduction in the marrow on day 15 (n = 87; P <.05). Multivariate analysis of the apoptosis-related parameters investigated, including spontaneous apoptosis, its inhibition by IL-7, and expression levels of Bcl-2 and Bax, showed that only IL-7 responsiveness has an independent impact on early cytoreduction (P <. 05), thus indicating a potential prognostic relevance of IL-7 sensitivity in T-ALL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891465

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.

Authors:  Sara González-García; Marta Mosquera; Patricia Fuentes; Tiziana Palumbo; Adela Escudero; Antonio Pérez-Martínez; Manuel Ramírez; Anne E Corcoran; Maria L Toribio
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

2.  Optimal interleukin-7 receptor-mediated signaling, cell cycle progression and viability of T-cell acute lymphoblastic leukemia cells rely on casein kinase 2 activity.

Authors:  Alice Melão; Maureen Spit; Bruno A Cardoso; João T Barata
Journal:  Haematologica       Date:  2016-07-28       Impact factor: 9.941

Review 3.  T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor?

Authors:  Emma Kroeze; Jan L C Loeffen; Vera M Poort; Jules P P Meijerink
Journal:  Blood Adv       Date:  2020-07-28

4.  Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.

Authors:  Valerie I Brown; Junjie Fang; Keith Alcorn; Rosalind Barr; Jenny M Kim; Robert Wasserman; Stephan A Grupp
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

5.  Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Amanda L Cleaver; Alex H Beesley; Martin J Firth; Nina C Sturges; Rebecca A O'Leary; Stephen P Hunger; David L Baker; Ursula R Kees
Journal:  Mol Cancer       Date:  2010-05-12       Impact factor: 27.401

6.  Absence of both IL-7 and IL-15 severely impairs the development of CD8 T cell response against Toxoplasma gondii.

Authors:  Rajarshi Bhadra; Hongbing Guan; Imtiaz A Khan
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

7.  Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors.

Authors:  Pablo Penaloza-MacMaster; Nicholas M Provine; Joshua Ra; Erica N Borducchi; Anna McNally; Nathaniel L Simmons; Mark J Iampietro; Dan H Barouch
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

8.  Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling.

Authors:  B A Cardoso; L R Martins; C I Santos; L M Nadler; V A Boussiotis; A A Cardoso; J T Barata
Journal:  Leukemia       Date:  2008-07-03       Impact factor: 11.528

Review 9.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

10.  STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.

Authors:  Daniel Ribeiro; Alice Melão; Ruben van Boxtel; Cristina I Santos; Ana Silva; Milene C Silva; Bruno A Cardoso; Paul J Coffer; João T Barata
Journal:  Blood Adv       Date:  2018-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.